Theravance Biopharma (TBPH) Interest Expenses (2016 - 2025)
Theravance Biopharma (TBPH) reported Interest Expenses of $582000.0 for Q4 2025, down 9.49% year-over-year from $643000.0 in Q4 2024, and up 1.57% quarter-over-quarter from $573000.0 in Q3 2025.
Theravance Biopharma (TBPH) Interest Expenses (2016 - 2025) Analysis & Trends
Theravance Biopharma (TBPH) has 10 years of Interest Expenses data on file, last reported at $582000.0 in Q4 2025.
- Interest Expenses for Q4 2025 came in at $582000.0, down 9.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.8 million (down 28.98% YoY), and the FY2025 annual result was $2.5 million, down 3.34% from the prior year.
- Interest Expenses grew to $582000.0 in Q4 2025 per TBPH's latest filing, from $573000.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $11.9 million in Q1 2021 and troughed at $550000.0 in Q4 2022.
- A 5-year average of $2.0 million and a median of $643000.0 in 2024 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2021 and 2022: Interest Expenses jumped 104.19% in 2021, then plunged 82.0% in 2022.
- A 5-year view of Interest Expenses shows it stood at $1.1 million in 2021, then sank by 48.36% to $550000.0 in 2022, then gained by 13.27% to $623000.0 in 2023, then advanced by 3.21% to $643000.0 in 2024, then fell by 9.49% to $582000.0 in 2025.
- Business Quant data shows TBPH's Interest Expenses at $582000.0 in Q4 2025, $573000.0 in Q3 2025, and $663000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -5.50 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 61,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -332,000.00 |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -2,753.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -5.58 Mn |
| 10 | Theravance Biopharma | 835.85 Mn | 441.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 582,000.00 |
| Dec 31, 2025 | 582,000.00 |
| Sep 30, 2025 | 573,000.00 |
| Sep 30, 2025 | 573,000.00 |
| Jun 30, 2025 | 663,000.00 |
| Jun 30, 2025 | 663,000.00 |
| Mar 31, 2025 | 643,000.00 |
| Mar 31, 2025 | 643,000.00 |
| Dec 31, 2024 | 643,000.00 |
| Dec 31, 2024 | 643,000.00 |
| Sep 30, 2024 | 630,000.00 |
| Sep 30, 2024 | 630,000.00 |
| Jun 30, 2024 | 644,000.00 |
| Jun 30, 2024 | 644,000.00 |
| Mar 31, 2024 | 629,000.00 |
| Mar 31, 2024 | 629,000.00 |
| Dec 31, 2023 | 623,000.00 |
| Dec 31, 2023 | 623,000.00 |
| Sep 30, 2023 | 609,000.00 |
| Sep 30, 2023 | 609,000.00 |